Applications
Alzheimer’s Disease
A debilitating disease without a cure
Million (worldwide currently live with Alzheimer’s Disease)
Billion euros (spent on Alzheimer’s and dementia globally)
Failed clinical trials in the past 14 years
Disease modifying treatments on the market
The Problem
Clinical trials in Azheimer’s Disease have been a graveyard for promising treatments
Invasive
90% of initially enrolled patients drop out of studies, mainly due to invasiveness and inconvenience of screening procedures
Inefficient
80% of screened patients are deemed unsuitable for trials after undergoing lengthy, risky, invasive procedures
Expensive
Screenings can cost as much as €2K per patient, totalling a screening spend of over €400M per year for clinical trials
No-Drug-Fits-All
Complex pathophysiology of disease and patient heterogeneity are often not accounted for in clinical trial design
How can we help?
Our blood-based screening test stratifies patients for clinical trials, removing heterogeneity due to underlying pathophysiology, disease stage or degree of progression. The iLoF Method offers:
40% cost savings
70% reduction of time spent on screenings
A non-invasive process for patient convenience
A pool of more qualified candidates, improving trial outcomes
Paving the way for personalised medicine
We believe the possibilities for the iLoF platform are endless. While Alzheimer’s is our current focus, we are building out our virtual fingerprint library and plan to bring the power of this technology to other diseases
COVID-19
Forecasting clinical outcomes and predicting severity of symptoms
Gastric Cancer
Stratifying cancer subtypes allowing for design and delivery of tailored treatments
Stroke
Differentiating between ischemic and hemorrhagic stroke patients for timely clinical management